Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
| 9/26/2024 | Peer Perform | Wolfe Research | |
| 9/5/2024 | Neutral | BTIG Research | |
| 6/24/2024 | Hold | Argus | |
| 5/30/2024 | $54.00 | Sell | Goldman |
ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, w
Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn., Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE:SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creating durable, accurately shaped, stain resistant attachments. "With the l
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai
Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00
Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00
Wolfe Research initiated coverage of Solventum Corporation with a rating of Peer Perform
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi
S-4 - Solventum Corp (0001964738) (Filer)
SCHEDULE 13G - Solventum Corp (0001964738) (Subject)
IRANNOTICE - Solventum Corp (0001964738) (Filer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)
UPS: -9% | United Parcel Service Q2 2024 Adj EPS $1.79 Misses $1.99 Estimate, Sales $21.820B Miss $22.183B Estimate SOLV: 6.9% | Solventum shares are trading higher following a report suggesting Trian has built a stake in the company. TUSK: 57% | Mammoth Energy Services shares are trading higher after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai
ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w
Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by